Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lifted by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,963 shares of the medical equipment provider’s stock after acquiring an additional 139 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Intuitive Surgical were worth $3,698,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Portside Wealth Group LLC boosted its position in Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in shares of Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after purchasing an additional 3,054 shares during the period. Kades & Cheifetz LLC purchased a new position in Intuitive Surgical during the fourth quarter valued at approximately $230,000. Blair William & Co. IL increased its stake in Intuitive Surgical by 3.1% in the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after buying an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after buying an additional 129,194 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ISRG shares. Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Mizuho upped their target price on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Jefferies Financial Group increased their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Finally, Raymond James lifted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Price Performance

ISRG stock opened at $377.08 on Wednesday. The company has a 50-day moving average of $386.54 and a two-hundred day moving average of $344.98. The stock has a market capitalization of $133.75 billion, a price-to-earnings ratio of 68.07, a price-to-earnings-growth ratio of 4.65 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.00 EPS. Equities analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.80% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.